Amneal Pharmaceuticals: Q1 Earnings Insights

Shares of Amneal Pharmaceuticals AMRX moved higher by 13% in pre-market trading after the company reported Q1 results.

Quarterly Results

Earnings per share rose 42.86% year over year to $0.20, which beat the estimate of $0.09.

Revenue of $498,533,000 rose by 11.75% from the same period last year, which beat the estimate of $444,230,000.

Looking Ahead

Amneal Pharmaceuticals hasn't issued any earnings guidance for the time being.

Revenue guidance hasn't been issued by the company for now.

How To Listen To The Conference Call

Date: May 11, 2020

Time: 08:00 PM ET

Webcast URL: https://event.on24.com/eventRegistration/EventLobbyServlet?target=reg20.jsp&referrer=https%3A%2F%2Finvestors.amneal.com%2Fevents-and-presentations%2Fdefault.aspx&eventid=2160261&sessionid=1&key=E914BD59C23EF549366ECD92AF31432F&regTag=&sourcepage=register

Price Action

Company's 52-week high was at $13.66

Company's 52-week low was at $2.27

Price action over last quarter: Up 7.39%

Company Overview

Amneal Pharmaceuticals Inc is a generic pharmaceutical manufacturer. The company's reportable segments are Generic Products and Specialty products. Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals, and Specialty segment is engaged in the development, promotion, sale and distribution of proprietary branded pharmaceutical products. It generates a majority of its revenue from the Generic business segment.